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Abstract
Most of the time, polycystic ovary syndrome (PCOs) is considered as an obese women
disease; lean PCOs patients need to evaluate and treat completely as a neglected subgroup.
Androgen excess signs and symptoms, insulin resistance (IR) and its consequences, cardio-
metabolic risks, and regular exercise must be noted and managed carefully.
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1. Introduction
Polycystic ovary syndrome (PCOs) is the most common reason of androgen excess in
reproductive-age women with a prevalence of 6.5–8% according to clinical appearance [1] or
even up to 20% by sonographic evidence [2].
For the first time, Stein and Leventhal described it in the year 1935 [3]. Year after year, the
description of the disease developed; in 1990, the National Institutes of Health (NIH) men-
tioned oligo-ovulation and hyperandrogenism with or without hyperandrogenemia (HA)
must be together (of course, after exclusion of another causes of androgen excess) [4].
Another expert meeting in 2003 expanded the NIH definition of PCOs by adding the sono-
graphic aspect of the disease (Rotterdam criteria) [5]. According to their criteria, two of three
signs/symptoms are necessary for PCOs diagnosis; therefore, PCOs woman can be ovulatory
with regular menstruation.
More recently, the Androgen Excess Society (AES) advocated that all of the signs and symp-
toms should be present for the confirmation of diagnose [6] (Table 1).
Contrary to physicians’ and patients’ belief, weight or body mass index (BMI) had never been
a part of PCOs definition.
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
According to epidemiological data, there is a wide variation in the prevalence of obese and
non-obese PCOs women: in Korean population 20%, in Europe 27–50.5%, and in USA 67% of
PCOs woman are obese [7–11]. Regarding to different ethnicity, the prevalence of normal
weight and underweight patients with PCOs has been reported 1.5–6.6% [12, 13]. Entirely, by
using Rotterdam criteria, the overall prevalence of PCOs is increasing because ovulatory or
non-hyper androgen PCO patients also are considered [14].
By definition, women with BMI ≤ 25 are non-obese and with BMI > 25 considered obese.
Although at now, we have a few reports about the prevalence of non-obese PCOs patients, but
attention toward those patients and theirmetabolic andhealth problems are enhancedday byday.
The pathophysiology of PCOs is multifactorial and manifests the final effect of genetic, fetal,
environmental, and metabolic factors. As a result of weakness or strength of each factor,
clinical and subclinical character and their response to therapeutic efforts will be different.
2. Genetic and PCOs
Obvious familial clustering of PCOs and higher prevalence of its sign and symptom, like type 2
diabetes mellitus (T2DM) and hyperandrogenemia in first-degree relatives of women with PCOs,
demonstrate its genetic origin [15, 16]. Also, in the Dutch twin study, higher degree of heritability
was shown [17]. Initially, autosomal dominant mode of inheritance was suggested [18]; but after a
while, researches demonstrate it has more complex inheritance pattern. Despite the progress in
genes or loci study, no single gene has been successfully described as the certain responsible gene
among all studies [19]. According to microarray analysis results, 14 important genes were recog-
nized: 6 genes were identified as down-regulated genes and 8 genes as up-regulated genes [20].
Another proposed genes are CYP11A, the insulin gene, and a region near the insulin-receptor
gene [21]. Also, controlling genes in folliculogenesis and LH receptor and coding genes for TNF-
alpha, IL-6, and IL-6 receptor can be involved in the pathogenesis of this syndrome [22].




(Rotterdam) 2003 (two of three) AES 2006 (all of them)
Hyperandrogenism  hyperandrogenemia Hyperandrogenismhyperandrogenemia Hyperandrogenism 
hyperandrogenemia
Oligo-ovulation Menstruation abnormality Ovarian dysfunction 
sonographic aspect
Sonographic aspect of poly cystic ovary
Exclusion of other androgen excess conditions is necessary for all of definition: (21-hydroxylase deficient, thyroid dys-
function, nonclassical adrenal hyperplasia, hyper prolactinemia, drug-induced androgen excess, androgenic neoplasm,
Cushing syndrome, growth hormone excess).
1European Society for Human Reproductive Medicine.
2American Society for Reproductive Medicine.
Table 1. Different definition of polycystic ovary syndrome.
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3. Insulin and PCOs
For the first time in 1980, the relation between this syndrome and insulin was determinate [23].
Clinically insulin resistance (IR) is specified as inability of a known amount of endogenous or
exogenous insulin to enhance glucose uptake and consumption. As a result of a misbelief that
IR always accompanies with obesity, in clinical practice, IR is underestimated in non-obese
PCO women. IR is a common character between obese and non-obese PCO patients and its
overall prevalence is 50–75%. Up to 35% of PCOs women have IGTT and 7–10% are type 2
diabetes mellitus (T2DM) [24].
At now, the most used IR indices are homeostasis-model assessment (HOMA) and insulinemic
2-h area under the curve (AUCi 2 h), both derived from oral glucose tolerance test (OGTT) [25].
The 120-min glucose and insulin evaluation (HOMA-M120) is the best IR index in lean PCOs
women according to Morciano et al. study [26]. Meanwhile, there are several earlier studies
about IR evaluation in lean PCOs women [27–29]. Although, a study in a large group of
European lean PCOs patients displayed that this group had significantly less IR compared
with obese PCO women [30]; but, instead of it, there is evidence that in American and Asian
PCOs women, IR is independent from BMI [31]. It seems that dietary composition and ethnic
background associated with this discrepancy.
Owing to another recent study, the crucial role of insulin in PCO pathogenesis empha-
sized that IR shall be evaluated even in normal weight and lean PCOs patients [12].
As suggested in the earlier study [32], hyperinsulinemia stimulates ovarian P450c17 alpha
activity in non-obese women with PCOs, which means more conversion of progesterone to
androstenedione which is changed to testosterone. In granulosa cell, insulin intensifies their
response to LH. Therefore, these cells experience premature arrest of follicular growth and
abnormal differentiation, and thus anovulation. Also, elevated insulin resistance causes hyper-
glycemia which leads to hyperinsulinemia and it can increase LH action on theca cells and
subsequent elevation in androgen level. Hyperinsulinemia, insulin resistance, and enhance-
ment in androgen production are the famous pathophysiology triads in PCOs. From another
side, elevated level of insulin prevents hepatic sex hormone-binding globulin (SHBG) produc-
tion, which can lead to elevated free androgen and again elevated level of insulin, a positive
feedback in an undesirable circle. Thus, IR and hyperinsulinemia are the principal pathological
causes of this syndrome, and hyperandrogenemia is their consequence.
As insulin resistance has fundamental role in non-obese PCOs patients, then metformin
administration have a beneficial effect on them and regulate their menstruation cycle [33]. As
well, there is a new therapeutic option: inositol, a precursor component of second messenger
for follicle-stimulating hormone (FSH), thyroid - stimulating hormone (TSH), and insulin recep-
tor. This drug can overcome IR from another way [34]. It is important to mention that only 15%
of women with IR are having PCOs criteria; therefore, insulin resistance cannot be the only
pathophysiologic pathway [35] and metformin administration may not be effective in all of
lean PCOs.
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4. Androgens and PCO
About 10–12% of women in reproductive age suffer from androgen excess sign and symptom.
It can be caused by androgen overproduction (from ovary or adrenal gland) or secondary to
increased sensitivity of pilosebaceous unit (with normal level of androgens). Hyperandrogenemia
is another hallmark of PCOs; mainly by ovarian resource and less by adrenal. In PCOs women,
60% of serum androstenedione and testosterone (T) are secreted by ovary. Surprising, ovarian
androgens will not prominently affect LH production, thus an elevation in free testosterone
or androstenedione will not decrease ovarian synthesis of these androgens in women, contrasting
to men.
As mentioned before, in PCO women, insulin in a solitary manner or with synergetic effect of
LH induces androgen production by ovaries. Even in lean PCOs women with normal meta-
bolic insulin sensitivity and insulin levels, decline of insulin secretion with diazoxide (like
metformin) prominently reduce levels of free Tand androstenedione andmeaningfully increased
SHBG [36]. In these women, hyperandrogenemia is seen because of augmented sensitivity of
their androgenic pathway to insulin and dysregulation of steroidogeneses enzymes based on
genetic predisposition [37]. Therefore, even in PCOs patients with normal insulin metabolic and
without clinical approved IR, local resistance in the ovaries increased androgens production [38].
Androgen excess or hyperandrogenemia (HA) in PCOs women contribute in exacerbation of
metabolic abnormalities, such as insulin resistance in adipose tissue and skeletal muscle and
elevation in lipid metabolism in visceral fat, decreased lipolysis in subcutaneous fat, increased
low-density lipoprotein cholesterol (LDL-C) levels decreased HDL-C levels. Besides that,
androgens may be involved in possible direct vascular action [39]. There are some studies, in
which hyperandrogenemia was accompanying with metabolic syndrome (MetS) in non-obese
PCOs more than obese PCOs women [40, 41].
Hyperandrogenemia or androgen access clinical signs are mainly cutaneous manifestations:
hirsutism, acne, androgenic alopecia, acanthosis nigricans (AN), and seborrhea. In one study,
their prevalence in PCOs women was: 78, 48, 31, 30, and 29% (in mentioned order) [42]. In
another study, the prevalence of acanthosis nigricans in obese PCO was 42.5% compared to
28% in non-obese [43]. One published paper shows that AN is a marker of hyperinsulinemia in
both obese and non-obese PCO patients rather than a sign of androgen excess and the only sex
steroid associated with histological AN is dehydroepiandrosterone sulfate (DHEAS) [44].
Pharmacological management of hyperandrogenic skin symptoms has two targets: firstly,
decrease the level of circulating androgens, and secondly prevent their effect at tissue level.
Cyproterone acetate/ethinylestradiol has beneficial effect in non-obese PCO women with
hyperandrogenic skin symptoms [45].
5. Inflammation and PCO
There are many published studies about proinflammatory or inflammatory situations in PCOs
woman. Increased level of circulatory inflammatory markers like C-reactive protein (CRP),
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tumor necrosis factor-alpha (TNF-α), interleukins (IL-16 and -18), and plasminogen activator
inhibitor in PCO patients accompany with abdominal obesity and more specific with visceral
fat [46]. Low-grade inflammation situation by increased level of adiponectin, resistin, IL-6,
and TNF-α in non-obese PCO women have been approved [47]. Also, it has been shown that
inhibition of nutrient-induced inflammation decreases ovarian androgen secretion and
induces ovulation in lean PCOs woman without clinical IR or abdominal adiposity. There-
fore, inflammation directly encourages ovarian dysfunction in PCOs women distinctly
from insulin resistance or excess adiposity [48]. There is evidence that non-steroidal
anti-inflammatory agent administration in lean PCO women can reduce androgen secretion
from ovary [49].
Dose inflammation have pathophysiologic role in this syndrome or may be its consequence
remain still unclear. Inflammation as a chronic immune activation, prevents ovulation,
increases androgen production by ovary and adrenal gland and disrupts hormonal receptors.
Most of long-term complications of PCOs like cardiovascular disease (CVD) are consequences
of inflammatory state [50].
In non-obese PCO patients, visceral fat distribution, waist to hip ratio (WHR), and abdominal
obesity have relation with inflammatory situation. In one study, in lean PCOs, level of white
blood cell (WBC) has a positive predictive value with insulin resistance, while the neutrophil to
lymphocyte ratio has a negative predictive value [51]. Also, it has been demonstrated that in
clomiphene citrate (CC)-resistant patients, regardless to BMI, inflammatory markers like TNF-
α are too high, and TNF-α serum level may be used as a clinical predictive indicator before CC
useless administration [52].
6. Weight and PCO
Even in lean PCO women, we can see higher waist to hip ratio, greater intra peritoneal
and visceral fat, and percentage of body fat in comparison with BMI matched non-PCO
women. Accumulation of small subcutaneous abdominal fat in those patients shows spoiled
adipogenesis and hyperandrogenism [53]. Also, abnormal gene expression in stem cell of sub-
cutaneous abdominal fat in normoandrogen and ovulatory lean PCO women display abnormal
vacuolization and angiogenesis, which may reflect metabolism alter in those women [54]. From
another side, adiponectin, a protein which is involved in regulating glucose levels and fatty acid
breakdown, is produced by omental fat and dysregulated by high level of insulin; thus, even
in lean PCOs women, inappropriate metabolism of glucose and lipid can be explained [55].
In respect with a new randomized controlled trial, arranged and regular physical exercise
can ameliorate insulin sensitivity, hyperandrogenemia, and menstrual regularity in lean PCO
women [56].
7. Metabolic disorders and PCO
PCOs is considered by multiple metabolic disorders which may associate to increase risk of
hypertension and cardiovascular disease. One study used menstrual irregularity as a predictive
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factor for assessment of cardiovascular events in a 15-year period, in PCOswomen. There was an
insignificant increase in overall stroke risk and in ischemic stroke risk associated with “very
irregular”menstrual cycles [57]. In PCO women, higher prevalence of hypertension is related to
insulin. Hyperinsulinemia have been connected with an increase in intracellular sodium and
calcium, along with vascular smooth muscle hypertrophy due to insulin-like growth factor-1
(IGF-1) activity [58]. Simultaneously, androgen excess stimulates sympathetic nerve activity, as
another etiology of hypertension in this population [59].
PCOs is also associated with elevated levels of plasma endothelin-1 (ET-1), one of several
circulating indicators of endothelial injury and dysfunction. One study found that impairment
of endothelial function is more severe in lean than obese women with PCOs, and that ET
receptor downregulation plays an essential role in this probably adverse cardiovascular out-
come [60].
The increase in carotid intima-media wall thickness (CIMT) in PCOs women has been associ-
ated in different studies with higher levels of insulin, hyperandrogenism, LDL level, and
abdominal obesity; which is an early marker of atherosclerosis [61].
Meanwhile, impaired nitric oxide (NO) production as a consequence of elevated androgen
levels in PCOs women contribute to endothelial dysfunction [62].
Elevated plasma viscosity as a result of increased plasma fibrinogen concentration in PCOs
patients exacerbates vascular dysfunction because autoregulation of vasomotor tone may not
be able to adjust with compromised physical properties of blood [63]. Some possible reasons
for increased plasma fibrinogen are: increased inflammatory processes [64], decreased fibrino-
lysis [65], and as an acute phase reactant. Enhancement in fibrinogen level stimulates RBC
aggregation and significantly increased resistance in blood flow [66]. Low SHBG and high
insulin stimulate prothrombotic state in all of PCOs women by increased plasminogen activa-
tor inhibitor 1 (PAI-1) activity and fibrinogen in a BMI-independent way [67].
Dyslipidemia including elevated low-density lipoprotein (LDL), triglyceride levels and decreased
high-density lipoprotein (HDL) are often seen in PCO women as a result of hyperandrogenism
and insulin resistance in both lean and obese PCO patients [68].
Owing to many evidence about vitamin D deficiency and metabolic syndrome; there are many
studies about 25(OH) D levels and PCOs. There are some evidences which support this
relationship and encourage vitamin D administration in all of deficient PCOs women [69],
whereas some studies do not support it [70].
From another site, insulin resistance, increased central adiposity, higher levels of testosterone,
and dyslipidemia beside oxidative stress and low grade inflammation contribute to cause
hepatic steatosis or fatty liver in PCOs women. Advanced stage of this disease characterized
by necrosis and steatohepatitis which called non-alcoholic fatty liver disease (NAFLD) and has
prevalence about 40% in lean PCOs women [71].
After blow-by-blow discussion about all of aspects in lean PCOs women, we cannot consider
this syndrome as just a part of infertility or menstrual abnormality assessment, but should be
accepted as an alarm sign for serious health problem.
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